The TRIM proteins in cancer: From expression to emerging regulatory mechanisms

• A. Mohammadi ^[6] ; M. S. Pour Abbasi ^[1] ; S. Khorrami ^[2] ; S. Khodamoradi ^[3] ; Z. Mohammadi Goldar ^[4] ; F. Ebrahimzadeh ^[5]
  1. [1] Kashan University of Medical Sciences

     Kashan University of Medical Sciences

     Irán

     
  2. [2] Tehran University of Medical Sciences

     Tehran University of Medical Sciences

     Irán

     
  3. [3] Islamic Azad University

     Islamic Azad University

     Irán

     
  4. [4] Qazvin University of Medical Sciences

     Qazvin University of Medical Sciences

     Irán

     
  5. [5] Mashhad University of Medical Sciences

     Mashhad University of Medical Sciences

     Irán

     
  6. [6] Department of Genetics Islamic, Azad University of Marand, Marand, Iran

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 3 (Marzo), 2022, págs. 460-470
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • New clinical evidence suggests that dysregulation of the ubiquitin-mediated destruction of tumor suppressors or oncogene products is probably engaged in the etiology of leukemia and carcinoma. The superfamily of tripartite motif (TRIM)-containing protein family is among the biggest recognized single protein RING finger E3 ubiquitin ligases that are considered vital carcinogenesis regulators, which is not shocking since TRIM proteins are engaged in various biological processes, including cell growth, development, and differentiation; hence, TRIM proteins’ alterations may influence apoptosis, cell proliferation, and transcriptional regulation. In this review article, the various mechanisms through which TRIM proteins exert their role in the most prevalent malignancies including lung, prostate, colorectal, liver, breast, brain cancer, and leukemia are summarized.